Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Moodys
Dow
McKesson
Boehringer Ingelheim
Express Scripts
AstraZeneca

Last Updated: May 28, 2022

Investigational Drug Information for SF1126


✉ Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug SF1126?

SF1126 is an investigational drug.

There have been 4 clinical trials for SF1126. The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2016.

The most common disease conditions in clinical trials are Head and Neck Neoplasms, Carcinoma, Squamous Cell, and Neuroblastoma. The leading clinical trial sponsors are SignalRX Pharmaceuticals, Inc., University of California, San Diego, and Semafore Pharmaceuticals.

There are twenty-one US patents protecting this investigational drug and ninety-four international patents.

Recent Clinical Trials for SF1126
TitleSponsorPhase
Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular CarcinomaUniversity of California, San DiegoPhase 1
Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular CarcinomaSignalRX Pharmaceuticals, Inc.Phase 1
SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway GenesSignalRX Pharmaceuticals, Inc.Phase 2

See all SF1126 clinical trials

Clinical Trial Summary for SF1126

Top disease conditions for SF1126
Top clinical trial sponsors for SF1126

See all SF1126 clinical trials

US Patents for SF1126

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
SF1126 See Plans and Pricing Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity The University of North Carolina at Chapel Hill (Chapel Hill, NC) See Plans and Pricing
SF1126 See Plans and Pricing Benzothiophene-based selective estrogen receptor downregulators The Board of Trustees of the University of Illinois (Urbana, IL) See Plans and Pricing
SF1126 See Plans and Pricing Benzothiophene estrogen receptor modulators G1 Therapeutics, Inc. (Research Park Triangle, NC) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
McKesson
Boehringer Ingelheim
Express Scripts
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.